Traders Purchase High Volume of Call Options on Kenvue (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE) saw unusually large options trading activity on Monday. Investors purchased 61,496 call options on the stock. This represents an increase of 564% compared to the average daily volume of 9,267 call options.

Wall Street Analyst Weigh In

A number of research firms have weighed in on KVUE. Barclays raised their price target on Kenvue from $21.00 to $23.00 and gave the company an “equal weight” rating in a research report on Thursday, March 27th. Piper Sandler increased their price objective on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday, February 24th. UBS Group cut their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Finally, Evercore ISI began coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an “in-line” rating and a $25.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $24.00.

Institutional Investors Weigh In On Kenvue

A number of large investors have recently made changes to their positions in the business. Grove Bank & Trust lifted its stake in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after acquiring an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new stake in shares of Kenvue in the 4th quarter worth about $29,000. SRS Capital Advisors Inc. lifted its position in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after purchasing an additional 571 shares during the period. Fortitude Family Office LLC boosted its stake in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc increased its position in shares of Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after buying an additional 1,441 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Down 0.6 %

NYSE:KVUE opened at $23.85 on Wednesday. The firm has a market capitalization of $45.57 billion, a P/E ratio of 44.99, a P/E/G ratio of 2.62 and a beta of 1.25. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company has a fifty day moving average of $22.44 and a 200 day moving average of $22.46. Kenvue has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, research analysts predict that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.44%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.